IL94055A - תכשירי רוקחות המכלים אונקוסטטין m לשינוי אימונוגניות של רקמות ולשיפורקליטת שתלים - Google Patents

תכשירי רוקחות המכלים אונקוסטטין m לשינוי אימונוגניות של רקמות ולשיפורקליטת שתלים

Info

Publication number
IL94055A
IL94055A IL9405590A IL9405590A IL94055A IL 94055 A IL94055 A IL 94055A IL 9405590 A IL9405590 A IL 9405590A IL 9405590 A IL9405590 A IL 9405590A IL 94055 A IL94055 A IL 94055A
Authority
IL
Israel
Prior art keywords
oncostatin
cells
pharmaceutical preparation
preparation according
expression
Prior art date
Application number
IL9405590A
Other languages
English (en)
Other versions
IL94055A0 (en
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/335,399 external-priority patent/US5202116A/en
Application filed by Oncogen filed Critical Oncogen
Priority to IL11276690A priority Critical patent/IL112766A/he
Priority to IL112767A priority patent/IL112767A/en
Priority to IL112768A priority patent/IL112768A/en
Publication of IL94055A0 publication Critical patent/IL94055A0/xx
Publication of IL94055A publication Critical patent/IL94055A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL9405590A 1989-04-10 1990-04-09 תכשירי רוקחות המכלים אונקוסטטין m לשינוי אימונוגניות של רקמות ולשיפורקליטת שתלים IL94055A (he)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL11276690A IL112766A (he) 1989-04-10 1990-04-09 תכשירי רוקחות המכילים אונקוסטטין m המיועדים להגברת פיברינוליזה וטרומבוליזה
IL112767A IL112767A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m
IL112768A IL112768A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/335,399 US5202116A (en) 1989-04-10 1989-04-10 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
US50448690A 1990-04-04 1990-04-04

Publications (2)

Publication Number Publication Date
IL94055A0 IL94055A0 (en) 1991-01-31
IL94055A true IL94055A (he) 1995-11-27

Family

ID=26989684

Family Applications (7)

Application Number Title Priority Date Filing Date
IL112768A IL112768A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
IL11276690A IL112766A (he) 1989-04-10 1990-04-09 תכשירי רוקחות המכילים אונקוסטטין m המיועדים להגברת פיברינוליזה וטרומבוליזה
IL9405590A IL94055A (he) 1989-04-10 1990-04-09 תכשירי רוקחות המכלים אונקוסטטין m לשינוי אימונוגניות של רקמות ולשיפורקליטת שתלים
IL112767A IL112767A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m
IL11276795A IL112767A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
IL11276895A IL112768A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
IL11276695A IL112766A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL112768A IL112768A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
IL11276690A IL112766A (he) 1989-04-10 1990-04-09 תכשירי רוקחות המכילים אונקוסטטין m המיועדים להגברת פיברינוליזה וטרומבוליזה

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL112767A IL112767A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m
IL11276795A IL112767A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
IL11276895A IL112768A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
IL11276695A IL112766A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m

Country Status (10)

Country Link
EP (1) EP0422186B1 (he)
JP (4) JPH04502769A (he)
AT (1) ATE174223T1 (he)
CA (1) CA2028825A1 (he)
DE (1) DE69032816T2 (he)
DK (1) DK0422186T3 (he)
ES (1) ES2124690T3 (he)
GR (6) GR1002178B (he)
IL (7) IL112768A (he)
WO (1) WO1990012585A1 (he)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
CA2055122A1 (en) * 1990-11-13 1992-05-14 Robert I. Grove Methods for stimulating ldl uptake and ldl receptor expression
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5241051A (en) * 1992-04-24 1993-08-31 Research Development Foundation Oncoinhibin
ATE250138T1 (de) * 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
EP1068224B1 (en) 1998-03-31 2005-05-11 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
EP1140204A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
WO2004043361A2 (en) * 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
ES2342529B1 (es) 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity

Also Published As

Publication number Publication date
IL112768A (en) 1998-06-15
IL112767A0 (en) 1995-05-26
EP0422186A1 (en) 1991-04-17
IL94055A0 (en) 1991-01-31
DK0422186T3 (da) 1999-08-16
GR1002187B (en) 1996-04-30
ATE174223T1 (de) 1998-12-15
GR920100456A (el) 1994-03-31
DE69032816T2 (de) 1999-07-29
ES2124690T3 (es) 1999-02-16
JPH1029948A (ja) 1998-02-03
GR920100455A (el) 1994-03-31
EP0422186A4 (en) 1993-09-15
JPH04502769A (ja) 1992-05-21
GR920100457A (el) 1994-03-31
GR900100278A (en) 1991-09-27
GR920100458A (el) 1994-03-31
GR1002185B (en) 1996-04-30
IL112767A (en) 1998-01-04
EP0422186B1 (en) 1998-12-09
GR1000968B (el) 1993-03-16
IL112768A0 (en) 1995-05-26
CA2028825A1 (en) 1990-10-11
WO1990012585A1 (en) 1990-11-01
GR920100459A (el) 1994-03-31
GR1002186B (en) 1996-04-30
GR1002182B (en) 1996-04-30
JPH1029949A (ja) 1998-02-03
IL112766A (he) 1996-06-18
GR1002178B (en) 1996-04-30
JPH1028595A (ja) 1998-02-03
DE69032816D1 (de) 1999-01-21
IL112766A0 (en) 1995-05-26

Similar Documents

Publication Publication Date Title
IL94055A (he) תכשירי רוקחות המכלים אונקוסטטין m לשינוי אימונוגניות של רקמות ולשיפורקליטת שתלים
Seckinger et al. A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha.
Cooper et al. IL-1 activity is reduced in psoriatic skin. Decreased IL-1 alpha and increased nonfunctional IL-1 beta.
Libby et al. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells
Mirshahi et al. SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models
Miossec et al. Interleukin‐1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid
Mortensen et al. Interaction of recombinant IL-1 and recombinant tumor necrosis factor in the induction of mouse acute phase proteins.
Dauchel et al. Expression of complement alternative pathway proteins by endothelial cells. Differential regulation by interleukin 1 and glucocorticoids
US5744442A (en) Regulation of cellular invasiveness
US5202116A (en) Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
JP2004043507A (ja) 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
Hass et al. Regulation of TNF-α, IL-1 and IL-6 synthesis in differentiating human monoblastoid leukemic U937 cells
Ismair et al. Autocrine regulation of matrix metalloproteinase-9 gene expression and secretion by tumor necrosis factor-α (TNF-α) in NB4 leukemic cells: specific involvement of TNF receptor type 1
Zoellner et al. Cytokine regulation of the synthesis of plasminogen activator inhibitor-2 by human vascular endothelial cells
Borish et al. Transthyretin is an inhibitor of monocyte and endothelial cell interleukin-1 production
Alessi et al. Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization
Christ et al. Type 1 plasminogen activator inhibitor synthesis of endothelial cells is downregulated by smooth muscle cells
Hakkert et al. Monocytes enhance the bidirectional release of type I plasminogen activator inhibitor by endothelial cells
Hansen et al. Epidermal interleukin 1α functional activity and interleukin 8 immunoreactivity are increased in patients with cutaneous T-cell lymphoma
Schneider et al. Basement membrane proteins in synovial membrane: distribution in rheumatoid arthritis and synthesis by fibroblast-like cells
Gallicchio et al. Stimulation of PAI-1 expression in endothelial cells by cultured vascular smooth muscle cells.
Brinckerhoff et al. Autocrine control of collagenase synthesis by synovial fibroblasts
De Prost Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells
AU766595B2 (en) Chemokine receptor antagonist and cyclosporin in combined therapy
Kojima et al. Lipopolysaccharide inhibits activation of latent transforming growth factor‐β in bovine endothelial cells

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH Patent void